Treatment of Advanced Metastatic Melanoma
The introduction in clinical practice of new drug compounds both targeted therapies anti-BRAF and checkpoint inhibitors have largely improved our potential to manage advanced metastatic melanoma patients. This has led to a significant improvement in terms of response rates and particularly in the ov...
Saved in:
Main Authors: | Pietro Quaglino (Author), Paolo Fava (Author), Luca Tonella (Author), Marco Rubatto (Author), Simone Ribero (Author), Maria Teresa Ferro (Author) |
---|---|
Format: | Book |
Published: |
Mattioli1885,
2021-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical and Pathological Relevance of Drug-induced Vitiligo in Patients Treated for Metastatic Melanoma with Anti-PD1 or BRAF/MEK Inhibitors
by: Alice Ramondetta, et al.
Published: (2020) -
Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy
by: Luca Mastorino, et al.
Published: (2022) -
Advances and Novel Treatment Options in Metastatic Melanoma
Published: (2022) -
A Case of a Pigmented Epithelioid Melanocytoma on a Mucosal Site
by: Alice Ramondetta, et al.
Published: (2020) -
Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
by: Simone Ribero, et al.
Published: (2019)